Financial Data and Key Metrics Changes - Total reported revenue for Q3 2025 was $700 million, a 4% decrease from $727 million in the prior year, primarily due to lower COVID and donor screening revenue [13][14] - Adjusted EBITDA was $177 million, with an adjusted EBITDA margin of 25%, reflecting a 180 basis point improvement year-over-year [10][17] - Adjusted diluted EPS was $0.80 for Q3, representing a 36% growth year-to-date [17][24] Business Line Data and Key Metrics Changes - Labs business revenue grew by 4%, driven by solid demand for VITROS, ImmunoAssay, and clinical chemistry platforms [6][9] - Immunohematology business grew by 5%, supported by strong demand from blood banks and hospitals [7] - Point-of-care business, particularly the Triage product line, posted 7% growth, with significant contributions from international markets [8][9] Market Data and Key Metrics Changes - North America revenue decreased by 12% overall, but increased by 5% year-over-year when excluding respiratory revenue and the U.S. donor screening exit [9] - Latin America experienced a 21% overall growth, with labs growing by 22% [9] - Japan, Asia-Pacific, and China each grew approximately 5%, while Europe, Middle East, and Africa grew by 3% [9] Company Strategy and Development Direction - The company is focused on margin improvement initiatives, achieving over $140 million in cost savings, aiming for sustainable mid to high 20s EBITDA margins [5][10] - Continued investment in strategic areas to position for long-term growth, including R&D advancements and new product launches [10][11] - The company is preparing for the anticipated FDA clearance of Lex Diagnostics by late 2025 or early 2026, which is expected to impact future growth [12][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress and the path ahead, emphasizing a focus on sustainable, profitable growth [12][24] - The company anticipates a typical respiratory season, with revenue timing consistent with pre-pandemic patterns [21][24] - Management acknowledged challenges from tariff impacts but remains committed to offsetting these in 2025 [11][19] Other Important Information - The company recorded a $701 million goodwill impairment charge in Q3, resulting in no goodwill remaining on the balance sheet [20] - Adjusted recurring cash flow is expected to represent 25-30% of adjusted EBITDA for the full year [19][24] - The company expects full-year 2025 total reported revenue between $2.68 billion and $2.74 billion, with adjusted EBITDA guidance of $585 million to $605 million [21][24] Q&A Session Summary Question: Can you provide more details on competitive wins? - Competitive wins have been evenly distributed across geographies, with significant wins in North America, Latin America, and EMEA, focusing on profitable growth rather than just market share [26][27] Question: What is the growth outlook for China? - The company expects mid-single-digit growth in China, with some impact from BBP and debundling dynamics, but less than competitors due to a high proportion of instruments used in stat labs [30][31] Question: Can you elaborate on the 2025 guidance and margin expectations? - The company narrowed its guidance while maintaining the same midpoint, with expectations for slightly lower margins in Q4 due to higher instrument revenue and incentive compensation [34][35] Question: What is the performance of the Sophia franchise? - The Sophia install base remains stable and expanding, with solid performance expected for the flu combo test in the upcoming respiratory season [43][44] Question: How will Lex Diagnostics impact margins? - Lex is expected to have a diluted impact on margins initially, with a more significant rollout planned for the second half of 2026 [50][51]

Financial Data and Key Metrics Changes - The company's third quarter revenue was approximately $1 billion, down 7% compared to the prior year [19] - Adjusted diluted earnings per share decreased by 19% to $2.92 [24] - Adjusted gross margin for the enterprise was 58.5%, down 110 basis points year-over-year, impacted by tariffs [21] - Adjusted operating margin was 20.8%, down 460 basis points compared to the prior year [24] Business Line Data and Key Metrics Changes - Crocs brand revenue was $836 million, down 3% year-over-year, with wholesale down 8% and direct-to-consumer (D2C) up 1% [19] - HEYDUDE brand revenue was $160 million, down 22% year-over-year, but better than expectations, with D2C down 1% [20] - International revenue for Crocs was up 4%, driven by a 23% increase in D2C performance [20] Market Data and Key Metrics Changes - North American revenues were down 9% year-over-year, with D2C down 8% and wholesale down 11% [20] - China delivered mid-20% revenue growth year-over-year, outperforming the overall market [13] - Strong growth was also observed in Japan and key markets in Western Europe [13] Company Strategy and Development Direction - The company is focusing on product innovation, particularly in clogs and sandals, and diversifying into new categories [9][10] - A strategic pullback on promotional activities is aimed at protecting brand health and driving future growth [5][6] - The company is leveraging digital and social marketing to enhance consumer engagement, including partnerships with the NFL and campaigns on TikTok [10][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a bifurcated North American consumer base, with affluent consumers continuing to purchase while others are more cautious [43] - The company expects revenue to decline approximately 8% in Q4, with Crocs brand down about 3% and HEYDUDE down in the mid-20% range [26] - Management is confident in returning HEYDUDE to profitability and growth despite recent challenges [38] Other Important Information - The company repurchased 2.4 million shares for $203 million during the quarter, representing about 4% of its float [25] - The company has identified $100 million in additional gross cost savings for 2026 [27] Q&A Session Summary Question: About incremental cost savings initiatives and structural deficiencies - Management highlighted efficiencies in the supply chain and reorganization efforts to drive cost savings and improve operating leverage [31][32] Question: Actions to drive improved results in North America - Management emphasized innovation in product categories and a focus on brand relevance to return to growth in North America [41][44] Question: Marketplace cleanup for HEYDUDE - Management confirmed ongoing cleanup actions in Q4, primarily through discount support, with expectations for improved sell-through [50][51] Question: Consumer spending behavior in Q4 - Management noted a cautious consumer environment, particularly among lower-income groups, impacting spending habits [60][62] Question: Store growth strategy for both brands - Management reported a pickup in store openings, particularly in Europe, with a focus on outlet stores [118][120]

Financial Data and Key Metrics Changes - Grupo Televisa's consolidated operating segment income margin expanded by 100 basis points year on year to 38.2%, driven by a year-on-year OpEx reduction of around 7% [4] - The leverage ratio improved to 2.1 times EBITDA from 2.5 times at the end of the previous year, primarily due to free cash flow generation [6] - Televisa Univision's third quarter revenue declined by 3% year on year to $1,300,000,000, while adjusted EBITDA increased by 9% to $460,000,000 [16][18] Business Line Data and Key Metrics Changes - The Internet subscriber base in Cable grew in the first nine months of the year compared to 2024, with a monthly churn rate below 2% for two consecutive quarters [4][10] - Cable's net revenue from residential operations was MXN 10,600,000,000, a decrease of only 0.7% year on year, marking the best quarter in two years [12] - Televisa Univision's consolidated advertising revenue decreased by 6% year on year, with a notable 11% decline in the U.S. [19] Market Data and Key Metrics Changes - Engagement and growth for VIX remained solid, with a high single-digit increase in MAUs driven by events like the Gold Cup semifinals [6] - In Mexico, advertising revenue increased by 3% year on year, primarily due to private and public sector ad sales [19] - The leverage and debt profile of Televisa Univision improved to 5.5 times EBITDA from 5.9 times in 2024, driven by growth [7] Company Strategy and Development Direction - The company focuses on attracting and retaining value customers in Cable, aiming for higher-end clients rather than volume [43] - Deleveraging remains a core strategic priority for Televisa Univision, with management committed to strengthening the capital structure [8] - The integration between EASI and Sky is expected to yield further synergies and operational efficiencies [4][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing integration and operational optimization at Televisa Univision, which is expected to create greater shareholder value [20] - The company acknowledges the rational nature of the competitive landscape in Mexico, with price increases being implemented across the industry [47][48] - Management highlighted the importance of local news and programming, exploring the inclusion of such content in their streaming platform [31] Other Important Information - The company generated around ARS 4,200,000,000 in free cash flow, allowing for the prepayment of a bank loan due in 2026 [5] - CapEx deployment for 2025 is budgeted at $600,000,000, with a reasonable CapEx to sales ratio of less than 20% [4][5] Q&A Session Summary Question: CapEx outlook for 2026 and insurance claim related to Hurricane Otis - Management provided guidance of around $600,000,000 for CapEx in 2025 and confirmed that the insurance claim related to Hurricane Otis is the last portion of that claim [22][24] Question: Local programming and advertising investments - Management acknowledged the importance of local news and is exploring its inclusion in the streaming platform, while also highlighting successful media for equity deals with startups [31][32] Question: Competition dynamics in the cable market - Management noted that the market is close to full penetration and emphasized a strategy focused on higher-end clients to maintain ARPU growth [43][44] Question: Sustainability of margins for Cable and Sky - Management indicated ongoing efforts to improve margins through technology and operational efficiencies, with confidence in sustaining high margins in the industry [62][63]

Financial Performance - Q4 Fiscal Year 2025 - Net sales increased by 1% to $2321 million compared to Q4 FY24[19, 68] - Organic net sales decreased by 3% compared to Q4 FY24[19, 68] - Adjusted EBIT decreased by 2% compared to Q4 FY24, reaching $321 million[19, 68] - Adjusted EPS decreased by 2% compared to Q4 FY24, amounting to $062[19, 68] Financial Performance - Full Fiscal Year 2025 - Net sales increased by 6% to $10253 million compared to FY24[19, 71] - Organic net sales decreased by 1% compared to FY24[19, 71] - Adjusted EBIT increased by 2% compared to FY24, reaching $1487 million[19, 71] - Adjusted EPS decreased by 4% compared to FY24, amounting to $297[19, 71] Segment Performance - Meals & Beverages organic net sales decreased by 3% in Q4 FY25[35] - Snacks organic net sales decreased by 2% in Q4 FY25[51] Fiscal Year 2026 Guidance - The company expects net sales to decline by 2% to 0%[109] - Organic net sales are projected to range from -1% to +1%[109] - Adjusted EBIT is expected to decline by 13% to 9%[109] - Adjusted EPS is projected to be in the range of $240 to $255[109]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $614 million, a decrease from $637 million in the prior year, primarily due to lower COVID and donor screening revenue [20][27] - Adjusted EBITDA increased by 19% year-over-year to $107 million, with an adjusted EBITDA margin improvement of 330 basis points to 17% [27] - Adjusted diluted EPS was $0.12, compared to a loss of $0.07 in the prior year, representing a growth of 271% [27] Business Line Data and Key Metrics Changes - The labs business grew by 5%, driven by strong performance in clinical chemistry and immunoassay testing [21] - Immunohematology revenue grew by 3%, with notable strength in Latin America and EMEA [22] - Respiratory business revenue decreased by $2 million, primarily due to a 52% decline in COVID sales [23] Market Data and Key Metrics Changes - North America revenue declined by 12% during the quarter, while international markets showed growth, particularly in Latin America (14% growth) and Japan/Asia Pacific (6% growth) [9][10] - China experienced 2% growth in Q2 despite tariff-related shipment holds, with expectations for mid-single-digit growth for the full year [11][12] Company Strategy and Development Direction - The company is focused on expanding its low OUS penetration as a significant growth opportunity [10] - Plans to acquire Lex Diagnostics to enhance its molecular diagnostics capabilities, with expected FDA clearance and market placements in 2026 [16][17] - Continued emphasis on cost structure optimization and operational improvements to drive profitability [12][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating tariff impacts, estimating potential headwinds of $20 million to $25 million for 2025, lower than previous estimates [15] - The company remains committed to delivering on its strategy to drive growth and expand profitability, with a focus on customer service and innovation [18][27] Other Important Information - The company completed its ERP conversion related to the business combination, which is expected to lower integration costs in the second half of the year [26] - The company anticipates annual operating cost savings of approximately $20 million from the consolidation of its New Jersey manufacturing site [26] Q&A Session Summary Question: Can you walk through your respiratory expectations for the remainder of the year? - The company is not changing flu assumptions, but COVID revenue guidance has been lowered due to lower emergency room visits and hospitalizations [35][36] Question: Can you provide insights on the visibility for China growth? - The company has good visibility for mid-single-digit growth in China, with minimal impact from recent pricing and volume actions [39][45] Question: What are the moving pieces affecting EBITDA? - The decrease in COVID revenue is offset by lower tariff impacts and the discontinuation of the Savannah platform, leading to no change in adjusted EBITDA guidance [48][51] Question: How is the company planning for the commercialization of the Lex platform? - No commercial efforts have started yet; the focus is on FDA approval before any marketing activities [92] Question: What is the outlook for free cash flow in the second half? - The company expects to generate more cash in the second half, targeting $140 million to $160 million of free cash flow [77][78]

Core Insights - Campbell's reported a 1% organic net sales growth for fiscal 2025 Q3, with adjusted EBIT increasing by 2% and adjusted EPS at $0.73, reflecting a 3% year-over-year decline, while full-year adjusted EPS is now expected at the low end of prior guidance [1] Meals and Beverages Performance - The meals and beverages segment achieved a 6% organic net sales growth and a 2% increase in consumption, marking six consecutive quarters of positive in-market consumption [2] - Strong household penetration gains in condensed cooking soups were noted, particularly among millennial consumers, with mac and cheese marketing adding approximately 1 million new households, the largest quarterly gain in four years for this subcategory [2][3] Snacks Segment Challenges - The snacks division experienced a 5% decline in organic net sales, with a 3% drop in consumption attributed to category-wide contraction and company-specific execution issues [4][5] - Recovery prospects for the snacks segment are now pushed into fiscal 2026, with management focusing on price-point strategies, multipack offerings, and targeted innovation to preserve share and margin [5] Cost Management and Acquisition Integration - The company achieved approximately $110 million in cost savings towards a $250 million multi-year target, with the SOVOS acquisition integration unlocking additional efficiencies [6][7] - Despite a 110 basis point contraction in adjusted gross profit margin, disciplined cost controls enabled a 2% adjusted EBIT gain, and acquisition synergies positively impacted adjusted EPS [6][8] Future Outlook - Management reaffirmed FY2025 guidance, now expecting adjusted EPS at the low end of the range, with meals and beverages facing shipment-related headwinds and snacks' full-year operating margin projected at 13% [8] - The FY2025 cost savings target has been raised to $130 million, and the company anticipates capital expenditures at approximately 4.5% of net sales, with tariff-related impacts on adjusted EPS estimated at $0.03–$0.05 [8]

Financial Data and Key Metrics Changes - Total reported revenue for Q1 2025 was $693 million, down from $711 million in the prior year, primarily due to lower COVID and donor screening revenue [18] - Excluding COVID and donor screening, the company achieved a mid single-digit revenue growth of 6% [18] - Adjusted EBITDA margin improved by 450 basis points year over year to 23%, with adjusted diluted EPS increasing by 68% to $0.74 [24][25] Business Line Data and Key Metrics Changes - Labs business, accounting for 54% of total revenue, grew by 7%, driven by clinical chemistry and immunoassay testing [10] - Immunohematology business grew by 4%, maintaining its global leadership position [10] - Point of Care business represented 25% of Q1 revenue and grew by 8% excluding COVID, with strong flu sales leading to an 18% year-over-year growth [10] - Molecular Diagnostics business grew by 11% excluding COVID, with ongoing clinical trials for the Savanna respiratory panel [11] Market Data and Key Metrics Changes - Revenue from the "Other" region (Japan, Asia Pacific, Latin America) grew by 12%, driven by a 17% increase in Labs revenue [19] - North America revenue declined by 6% due to lower COVID revenue and donor screening wind down, but grew by 5% when excluding these factors [19] - Europe, Middle East, and Africa grew by 9%, while China revenue remained flat, primarily due to order timing and decreased Triage revenue [20] Company Strategy and Development Direction - The company is focused on a narrow set of strategic initiatives, including increasing platform content and utility, expanding margins, and enhancing commercial execution [11] - Plans to realize $100 million in annualized cost savings, with $50 million expected in the first half of 2025 [12] - The company aims to maintain its manufacturing footprint and continue investing in U.S.-based manufacturing and R&D [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and operational discipline, highlighting strong Q1 results and ongoing initiatives [9] - The company anticipates potential tariff impacts of $30 million to $40 million in 2025 but believes mitigation plans will offset these impacts [15] - Full-year 2025 financial guidance remains unchanged, with expectations for total reported revenue between $2.6 billion and $2.81 billion [27] Other Important Information - The company has invested nearly $1 billion in U.S.-based manufacturing and R&D over the past three years [13] - Adjusted free cash flow for Q1 2025 was $47 million, representing 29% of adjusted EBITDA [26] - The company plans to refinance its debt in the second half of 2025 or early 2026, depending on market conditions [31] Q&A Session Summary Question: Can you elaborate on the tariff impact and pricing actions? - Management indicated that selective pricing actions are being considered to offset tariff impacts, but competitive market conditions must be taken into account [36][37] Question: Will tariff impacts affect long-term manufacturing plans? - Management does not expect changes to the overall manufacturing footprint, emphasizing the importance of their global manufacturing network [38] Question: How confident is the company in mitigating tariff impacts? - Management expressed confidence in fully mitigating tariff impacts through various actions, including cost reductions and realigning inventories [43] Question: What underpins the confidence in China's growth rate? - Confidence in mid to high single-digit growth in China is based on strong performance in labs and immunohematology, despite some softness in Triage sales [49] Question: What is the status of the Savanna program? - The company is focused on completing the RBP4x submission to the FDA and is not speculating on outcomes beyond that [45][61] Question: How is the respiratory sales performance impacting guidance? - Management expects to maintain the guidance range for COVID revenue despite a decline, as flu sales have been strong [56][58]

Core Viewpoint - Alto Ingredients, Inc. reported improved year-over-year gross margin and Adjusted EBITDA for Q1 2025, driven by operational efficiencies from its recent acquisition of Alto Carbonic and a corporate reorganization aimed at cost savings [2][4]. Financial Performance - Net sales for Q1 2025 were $226.5 million, down from $240.6 million in Q1 2024 [8][14]. - Cost of goods sold decreased to $228.3 million from $243.0 million, resulting in a gross loss of $1.8 million compared to a gross loss of $2.4 million in the previous year [8][14]. - Selling, general and administrative expenses were reduced to $7.2 million from $7.9 million [8][14]. - The net loss attributable to common stockholders was $12.0 million, or $0.16 per share, compared to a net loss of $12.0 million, or $0.17 per share, in the prior year [8][14]. Operational Highlights - The acquisition of Alto Carbonic has led to lower combined costs and improved operational coordination, contributing to an expected annual savings of approximately $8 million starting Q2 2025 [2][3]. - The company shifted production to ISCC renewable fuel for European markets, which is experiencing strong demand, partially offsetting the domestic softening of premiums on high-quality alcohol and essential ingredients [3][4]. Cash and Liquidity - Cash and cash equivalents were reported at $26.8 million as of March 31, 2025, down from $35.5 million at the end of 2024 [5][16]. - The company's borrowing availability stood at $76.7 million, including $11.7 million under the operating line of credit and $65.0 million under its term loan facility [5][16]. Market Metrics - Total renewable fuel gallons sold decreased to 65.3 million in Q1 2025 from 72.7 million in Q1 2024 [19]. - The average sales price per gallon for alcohol increased to $1.93 from $1.86 year-over-year [20]. - Essential ingredients sold totaled 310.8 thousand tons, slightly down from 313.4 thousand tons in the previous year [20].

Financial Data and Key Metrics Changes - Adjusted earnings per share for Q2 2025 was $1.90, up 7% compared to $1.78 in Q2 2024, and up 10% for the first half of fiscal 2025 compared to the same period in fiscal 2024 [5][14] - Cash flow from operations was $73 million, with discretionary free cash flow at $110 million, and a cash balance of $213 million at the end of the quarter [14][15] - The company announced a 5% increase in its quarterly dividend, marking ten consecutive years of annual dividend increases [9][24] Business Segment Data and Key Metrics Changes - EBIT in Reinforcement Materials was $131 million, down 12% year-over-year, primarily due to lower tire demand [6][15] - Performance Chemicals saw EBIT increase by 61% year-over-year, driven by improved margins and higher volumes, particularly in the fumed silica product line [6][7] - Year-over-year volume growth of 10% was achieved in the battery materials product line during the first half of fiscal 2025 [8] Market Data and Key Metrics Changes - In The Americas, volumes were down 9%, with South America experiencing a significant decline due to lower contract outcomes [15][29] - Asia Pacific volumes decreased by 8%, primarily driven by reduced production during the Lunar New Year holiday [30] - European volumes remained flat year-over-year, with some gains in the contract season [32] Company Strategy and Development Direction - The company is focusing on high-performance segments in China and developing business with customers building battery plants in Western economies [8][12] - The "Creating for Tomorrow" strategy aims to position the company for long-term shareholder value creation [12][24] - The company is executing fixed cost and procurement initiatives expected to contribute $30 million in savings for fiscal 2025 [12][21] Management's Comments on Operating Environment and Future Outlook - Management noted that the current tariff landscape is dynamic, causing customers to adopt a cautious posture regarding inventory levels [11][19] - The company expects volumes in Reinforcement Materials to decline in the low single-digit percentage for the fiscal year, while Performance Chemicals is expected to see low single-digit percentage growth [22][24] - Despite uncertainties, management remains confident in the company's fundamentals and cash generation capabilities [24][25] Other Important Information - Capital expenditures for Q2 2025 were $72 million, with a revised full-year forecast of $250 million to $275 million [14][66] - The company maintains a strong liquidity position of approximately $1.2 billion [15] Q&A Session Summary Question: Can you provide context on the reinforcement volume changes? - Management explained that the volume picture varies by region, with significant declines in South America and a more cautious approach from customers in North America [27][28] Question: How do volumes split between North America and South America in the Reinforcement Materials segment? - Management indicated that approximately 60% of volumes come from North America and 40% from South America, with South American volumes down sharply [38][39] Question: What are the underlying price dynamics in the Reinforcement Materials segment? - Pricing remains largely flat due to contract negotiations, with steady margins in Asia Pacific's spot market [41][42] Question: What is the expected impact on energy center revenues? - Management expects a mid-single-digit million impact headwind in the second half due to declining oil prices [44] Question: Can you elaborate on the cost savings initiatives? - The $30 million in cost savings includes a mix of temporary and structural measures, with most savings expected to be recognized in the second half of the year [54][56] Question: What is the current capacity utilization across the industry? - Capacity utilization varies by region, with North America in the low 80s, Europe in the upper 80s, and Asia Pacific around 90% [62][63]

Financial Data and Key Metrics Changes - Adjusted earnings per share for Q2 2025 increased by 7% to $1.9 compared to Q2 2024, with a 10% growth in the first half of fiscal 2025 compared to the same period in fiscal 2024 [5][14][25] - EBIT in Reinforcement Materials was $131 million, up 1% sequentially but down 12% year over year [6][16] - EBIT in Performance Chemicals increased by 61% year over year, driven by improved margins and higher volumes [6][18] Business Line Data and Key Metrics Changes - Reinforcement Materials experienced a 7% decline in global volumes year over year, with regional declines of 9% in The Americas, 8% in Asia Pacific, and 1% in Europe [16][17] - Performance Chemicals saw a 4% increase in volumes year over year, particularly in the fumed silica product line [18] Market Data and Key Metrics Changes - The Americas market was heavily influenced by South America, where lower contract volumes were noted, while North America saw a small decline in volumes due to weak demand [30] - In Asia, volumes were down 8%, primarily due to a more normalized Lunar New Year holiday and cautious production adjustments by customers [31] Company Strategy and Development Direction - The company is focusing on high-performance segments in China and developing business with customers building battery plants in Western economies [7][12] - A 5% increase in quarterly dividends was announced, consistent with the capital allocation framework to increase dividends as earnings grow [9][25] - The company is executing fixed cost and procurement initiatives expected to contribute $30 million in savings for fiscal 2025 [12][21] Management's Comments on Operating Environment and Future Outlook - Management noted that the current tariff landscape is dynamic, causing customers to adopt a cautious posture regarding inventory levels [11][20] - The company expects volumes in Reinforcement Materials to decline in the low single-digit percentage for the fiscal year, while Performance Chemicals is expected to see low single-digit percentage growth [22][24] Other Important Information - Cash flow from operations was $73 million, with discretionary free cash flow of $110 million for the quarter [15] - Capital expenditures for Q2 2025 were $72 million, with a full-year forecast of $250 million to $275 million [15][67] Q&A Session Summary Question: Can you provide insight on the reinforcement volume changes? - Management explained that the volume picture varies by region, with significant declines in South America and a small decline in North America due to economic uncertainty [28][30][34] Question: How do volumes split between North America and South America? - Management indicated that approximately 60% of volumes come from North America and 40% from South America, with South American volumes down sharply [40][42] Question: What are the underlying price dynamics in the Reinforcement Materials segment? - Pricing is largely flat due to contract negotiations, with steady margins in Asia Pacific but lower than in the West [43][45] Question: What is the expected impact on energy center revenues? - Management expects some impact in the second half due to declining oil prices, with a mid-single-digit million headwind anticipated [46] Question: How is the seasonal trend expected to play out in Performance Chemicals? - Management noted that while seasonal trends remain, customers are exhibiting caution in inventory levels due to tariff uncertainties [52][55] Question: What is the current capacity utilization across the industry? - Capacity utilization varies by region, with North America in the low 80s, Europe in the upper 80s, and Asia Pacific around 90%, but a cautious approach is expected to lower these levels [62][64][66] Question: How is the CapEx split between growth and maintenance? - Approximately $100 million of the $250 million to $275 million CapEx is growth-related, primarily for new capacity in Indonesia [68]